Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TAAR1 | Q96RJ0 | 10/20 | 0.52 |
| ▸ | HTR2A | P28223 | 1/20 | 0.52 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.47 |
| ▸ | ADRA2A | P08913 | 2/20 | 0.47 |
| ▸ | MAPT | P10636 | 2/20 | 0.47 |
| ▸ | DRD2 | P14416 | 2/20 | 0.47 |
| ▸ | DRD1 | P21728 | 2/20 | 0.47 |
| ▸ | DRD4 | P21917 | 2/20 | 0.47 |
| ▸ | DRD5 | P21918 | 2/20 | 0.47 |
| ▸ | SLC6A2 | P23975 | 2/20 | 0.47 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.47 |
| ▸ | DRD3 | P35462 | 2/20 | 0.47 |
| ▸ | RECQL | P46063 | 2/20 | 0.47 |
| ▸ | SLC6A3 | Q01959 | 2/20 | 0.47 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.47 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.47 |
| ▸ | PNMT | P11086 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.47 |
| ▸ | TP53 | P04637 | 1/20 | 0.47 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL17823096 | 0.98 | TAAR1 (0.50) | TAAR1HTR2AKDM4EADRA2AMAPT | |
| SCHEMBL51845 | 0.84 | KDM4E (0.47) | TAAR1HTR2AKDM4ECYP2D6PNMT | |
| SCHEMBL3400966 | 0.84 | KDM4E (0.47) | TAAR1HTR2AKDM4ECYP2D6PNMT | |
| SCHEMBL1128476 | 0.83 | TAAR1 (0.52) | TAAR1HTR2AKDM4EADRA2AMAPT | |
| Hydrochloric Acid SCHEMBL148514 | 0.83 | KDM4E (0.46) | TAAR1HTR2AKDM4EMAPTCYP2D6 | |
| SCHEMBL4444493 | 0.83 | CYP1A2 (0.46) | TAAR1HTR2AKDM4ETDP1CYP2D6 | |
| SCHEMBL5705931 | 0.82 | TAAR1 (0.56) | TAAR1HTR2AKDM4EADRA2AMAPT | |
| SCHEMBL30496702 | 0.82 | TAAR1 (0.56) | TAAR1HTR2AKDM4EADRA2AMAPT | |
| SCHEMBL4599785 | 0.81 | CYP1A2 (0.53) | KDM4EMAPTTDP1CYP2D6ALDH1A1 | |
| SCHEMBL2657319 | 0.81 | CYP1A2 (0.53) | KDM4ECYP2D6ALDH1A1TP53HSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 38 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3463362-B1 | SUBSTITUTED TETRAHYDROISOQUINOLINE COMPOUNDS USEFUL AS GPR120 AGONISTS | MERCK SHARP & DOHME LLC (US) | 2025-09-03 | — | — | EP | disclosed |
| US-11161819-B2 | Substituted tetrahydroisoquinoline compounds useful as GPR120 agonists | MERCK SHARP & DOHME CORP. (US) | 2021-11-02 | — | — | US | disclosed |
| US-20200347020-A1 | SUBSTITUTED TETRAHYDROISOQUINOLINE COMPOUNDS USEFUL AS GPR120 AGONISTS | MERCK SHARP & DOHME CORP. (US) | 2020-11-05 | — | — | US | disclosed |
| US-10316036-B2 | Substituted pyrazino[2,2-a]isoquinoline derivatives | HOFFMANN-LA ROCHE INC. (US) | 2019-06-11 | — | — | US | disclosed |
| US-20190161448-A1 | SUBSTITUTED TETRAHYDROISOQUINOLINE COMPOUNDS USEFUL AS GPR120 AGONISTS | MERCK SHARP & DOHME CORP. (US) | 2019-05-30 | — | — | US | disclosed |
| EP-3463362-A1 | SUBSTITUTED TETRAHYDROISOQUINOLINE COMPOUNDS USEFUL AS GPR120 AGONISTS | Merck Sharp & Dohme Corp. (US) | 2019-04-10 | — | — | EP | disclosed |
| EP-3186250-B1 | SUBSTITUTED PYRAZINO[2,1-A]ISOQUINOLINE DERIVATIVES FOR THE TREATMENT OF CNS DISORDERS | HOFFMANN LA ROCHE (CH) | 2018-04-18 | — | — | EP | disclosed |
| US-20180037582-A1 | SUBSTITUTED PYRAZINO[2,2-a]ISOQUINOLINE DERIVATIVES | HOFFMANN-LA ROCHE INC. (US) | 2018-02-08 | — | — | US | disclosed |
| WO-2017205193-A1 | SUBSTITUTED TETRAHYDROISOQUINOLINE COMPOUNDS USEFUL AS GPR120 AGONISTS | MERCK SHARP & DOHME CORP. (US) | 2017-11-30 | — | — | WO | disclosed |
| WO-2017201683-A1 | SUBSTITUTED TETRAHYDROISOQUINOLINE COMPOUNDS USEFUL AS GPR120 AGONISTS | MERCK SHARP & DOHME CORP. (US) | 2017-11-30 | — | — | WO | disclosed |
| WO-2009100168-A1 | DUAL PHARMACOPHORES - PDE4-MUSCARINIC ANTAGONISTICS | GLAXO GROUP LIMITED (GB) | 2009-08-13 | — | — | WO | disclosed |
| WO-2009100169-A1 | DUAL PHARMACOPHORES - PDE4-MUSCARINIC ANTAGONISTICS | GLAXO GROUP LIMITED (GB) | 2009-08-13 | — | — | WO | disclosed |
| WO-2009100167-A1 | DUAL PHARMACOPHORES-PDE4-MUSCARINIC ANTAGONISTICS | GLAXO GROUP LIMITED (GB) | 2009-08-13 | — | — | WO | disclosed |
| WO-2009100170-A1 | DUAL PHARMACOPHORES - PDE4-MUSCARINIC ANTAGONISTICS | GLAXO GROUP LIMITED (GB) | 2009-08-13 | — | — | WO | disclosed |
| US-20090197871-A1 | Dual Pharmacophores - PDE4-Muscarinic Antagonistics | GLAXO GROUP LIMITED (GB) | 2009-08-06 | — | — | US | disclosed |
| CN-101379022-A | Benzamide and heteroarene derivatives | HOFFMANN LA ROCHE (CH) | 2009-03-04 | — | — | CN | disclosed |
| US-20070185058-A1 | Heteroaryl and benzyl amide compounds | HOFFMANN-LA ROCHE INC. | 2007-08-09 | — | — | US | disclosed |
| EP-1112998-B1 | AMINE DERIVATIVES | POLA CHEM IND INC (JP) | 2004-12-08 | — | — | EP | disclosed |
| US-6586633-B1 | Antifungal agents | POLA CHEMICAL INDUSTRIES, INC. (JP) | 2003-07-01 | — | — | US | disclosed |
| EP-1112998-A1 | AMINE DERIVATIVES | POLA CHEMICAL INDUSTRIES, INC. (JP) | 2001-07-04 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190161448-A1 | SUBSTITUTED TETRAHYDROISOQUINOLINE COMPOUNDS USEFUL AS GPR120 AGONISTS | GPR119, GPR88, GPR180 | TAAR1 214/4885HTR2A 327/4885KDM4E 3605/4885 |
| US-20180037582-A1 | SUBSTITUTED PYRAZINO[2,2-a]ISOQUINOLINE DERIVATIVES | HCRTR2, HCRTR1, CYP11B2 | TAAR1 199/4885HTR2A 10/4885KDM4E 1161/4885 |
| US-11161819-B2 | Substituted tetrahydroisoquinoline compounds useful as GPR120 agonists | GPR119, GPR88, GPR180 | TAAR1 185/4885HTR2A 311/4885KDM4E 3506/4885 |
| US-20070185058-A1 | Heteroaryl and benzyl amide compounds | CYP1B1, CYP4B1, ABCG2 | TAAR1 1530/4885HTR2A 755/4885KDM4E 1993/4885 |
| US-20200347020-A1 | SUBSTITUTED TETRAHYDROISOQUINOLINE COMPOUNDS USEFUL AS GPR120 AGONISTS | GPR119, GPR88, GPR180 | TAAR1 185/4885HTR2A 311/4885KDM4E 3506/4885 |
| US-20090197871-A1 | Dual Pharmacophores - PDE4-Muscarinic Antagonistics | PDE4B, PDE4A, CHRM4 | TAAR1 269/4885HTR2A 920/4885KDM4E 1070/4885 |
| US-10316036-B2 | Substituted pyrazino[2,2-a]isoquinoline derivatives | HCRTR2, HCRTR1, CYP11B2 | TAAR1 199/4885HTR2A 10/4885KDM4E 1161/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.